Nicolas F. Schlecht

Dr. Nicolas F. Schlecht

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
NSNicolas F. Schlecht
Nicolas F. Schlecht
MBMargaret Brandwein-Gensler
Margaret Brandwein-Gensler
GNGerard J Nuovo
Gerard J Nuovo
MLMaomi Li
Maomi Li
ADAnne Dunne
Anne Dunne
MPMichael B Prystowsky
Michael B Prystowsky
Detection of human papillomavirus (HPV) in head and neck cancer has therapeutic implications. In situ hybridization and immunohistochemistry for p16 are used by surgical pathologists. We compared the sensitivity and specificity of three popular commercial tests for HPV detection in head and neck squamous cell carcinomas with a ‘gold standard’ HPV PCR assay. A total of 110 prospectively collected, formalin-fixed tumor specimens were compiled onto tissue microarrays and tested for HPV DNA by in situ hybridization with two probe sets, a biotinylated probe for high-risk (HR) HPV types 16/18 (Dako, CA, USA) and a probe cocktail for 16/18, plus 10 additional HR types (Ventana, AZ, USA). The p16INK4 expression was also assessed using a Pharmingen immunohistochemistry antibody (BD Biosciences, CA, USA). Tissue microarrays were stained and scored at expert laboratories. HPV DNA was detected by MY09/11-PCR, using Gold AmpliTaq and dot-blot hybridization on matched-fresh frozen specimens in a research laboratory. HPV 16 E6 and E7-RNA expression was also measured using RT-PCR. Test performance was assessed by a receiver operating characteristic analysis. HR-HPV DNA types 16, 18 and 35 were detected by MY-PCR in 28% of tumors, with the majority (97%) testing positive for type 16. Compared with MY-PCR, the sensitivity and specificity for HR-HPV DNA detection with Dako in situ hybridization was 21% (95% confidence interval (CI): 7–42) and 100% (95% CI: 93–100), respectively. Corresponding test results by Ventana in situ hybridization were 59% (95% CI: 39–78) and 58% (95% CI: 45–71), respectively. The p16 immunohistochemistry performed better overall than Dako (P=0.042) and Ventana (P=0.055), with a sensitivity of 52% (95% CI: 32–71) and specificity of 93% (95% CI: 84–98). Compared with a gold standard HPV-PCR assay, HPV detection by in situ hybridization was less accurate for head and neck squamous cell carcinoma on tissue microarrays than p16 immunohistochemistry. Further testing is warranted before these assays should be recommended for clinical HPV detection.

5 April 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CSChristian R. Salazar
Christian R. Salazar
NANicole Anayannis
Nicole Anayannis
RSRichard V. Smith
Richard V. Smith
YWYanhua Wang
Yanhua Wang
MHMissak Haigentz
Missak Haigentz
NSNicolas F. Schlecht
Nicolas F. Schlecht
While its prognostic significance remains unclear, p16INK4a protein expression is increasingly being used as a surrogate marker for oncogenic human papillomavirus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). To evaluate the prognostic utility of p16 expression in HNSCC, we prospectively collected 163 primary tumor specimens from histologically confirmed HNSCC patients who were followed for up to 9.4 years. Formalin fixed tumor specimens were tested for p16 protein expression by immunohistochemistry (IHC). HPV type‐16 DNA and RNA was detected by MY09/11‐PCR and E6/E7 RT‐PCR on matched frozen tissue, respectively. P16 protein expression was detected more often in oropharyngeal tumors (53%) as compared with laryngeal (24%), hypopharyngeal (8%) or oral cavity tumors (4%; p < 0.0001). With respect to prognosis, p16‐positive oropharyngeal tumors exhibited significantly better overall survival than p16‐negative tumors (log‐rank test p = 0.04), whereas no survival benefit was observed for nonoropharyngeal tumors. However, when both p16 and HPV DNA test results were considered, concordantly positive nonoropharyngeal tumors had significantly better disease‐specific survival than concordantly negative nonoropharyngeal tumors after controlling for sex, nodal stage, tumor size, tumor subsite, primary tumor site number, smoking and drinking [adjusted hazard ratio (HR) = 0.04, 0.01–0.54]. Compared with concordantly negative nonoropharyngeal HNSCC, p16(+)/HPV16(−) nonoropharyngeal HNSCC (n = 13, 7%) demonstrated no significant improvement in disease‐specific survival when HPV16 was detected by RNA (adjusted HR = 0.83, 0.22–3.17). Our findings show that p16 IHC alone has potential as a prognostic test for oropharyngeal cancer survival, but combined p16/HPV testing is necessary to identify HPV‐associated nonoropharyngeal HNSCC with better prognosis.

23 December 2018 in Head & Neck
Verified
Journal Article
Closed access
PDF file
MFMichael Fattouh
Michael Fattouh
GCGina Y. Chang
Gina Y. Chang
TOThomas J. Ow
Thomas J. Ow
KSKeivan Shifteh
Keivan Shifteh
GRGregory Rosenblatt
Gregory Rosenblatt
NSNicolas F. Schlecht
Nicolas F. Schlecht

4 September 2013 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
CSChristian R. Salazar
Christian R. Salazar
RSRichard V. Smith
Richard V. Smith
MGMadhur K. Garg
Madhur K. Garg
MHMissak Haigentz
Missak Haigentz
BSBradley A. Schiff
Bradley A. Schiff
NSNicolas F. Schlecht
Nicolas F. Schlecht

14 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
HRHilary A. Robbins
Hilary A. Robbins
AFAida Ferreiro-Iglesias
Aida Ferreiro-Iglesias
TWTim Waterboer
Tim Waterboer
NBNicole Brenner
Nicole Brenner
MNMari Nygård
Mari Nygård
PBPaul Brennan
Paul Brennan
PURPOSE: Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown.METHODS: We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality.RESULTS: The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age 50 years was 17.4% (95% CI, 12.4 to 28.6) and at age 60 years was 27.1% (95% CI, 19.2 to 45.4). Corresponding 5-year risk estimates were 7.3% and 14.4%, respectively. For HPV16-E6 seropositive females, 10-year risk estimates were 3.6% (95% CI, 2.5 to 5.9) at age 50 years and 5.5% (95% CI, 3.8 to 9.2) at age 60 years and 5-year risk estimates were 1.5% and 2.7%, respectively. Over 30 years, after a seropositive result at age 50 years, an estimated 49.9% of males and 13.3% of females would develop OPC. By contrast, 10-year risks among HPV16-E6 seronegative people were very low, ranging from 0.01% to 0.25% depending on age, sex, and smoking status.CONCLUSION: We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC, with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test, particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance remains to be established.

1 May 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
RLRoberto A. Lleras
Roberto A. Lleras
LALeslie R. Adrien
Leslie R. Adrien
RSRichard Vance Smith
Richard Vance Smith
BBBenjamin Brown
Benjamin Brown
NJNaheed Jivraj
Naheed Jivraj
TBThomas James Belbin
Thomas James Belbin